Moberg Pharma: Strong subscription rate for Warrants - Redeye

Redeye comments on the outcome of the T02 and the directed issue to the top guarantors, which brought in a strong SEK 336m before costs. We adjusted the number of shares and increased the total proceeds from the TO2 and direct issue while adjusting our top US sales assumption slightly to align more with the company-stated targets. This brings our Base case to SEK 29 (24.5) per share, with Bear and Bull cases at SEK 10 and SEK 52, respectively.

Länk till analysen i sin helhet: https://www.redeye.se/research/1016948/moberg-pharma-strong-subscription-rate-for-warrants?utm_source=finwire&utm_medium=RSS